Oruka Therapeutics, Inc. (ORKA)
NASDAQ:ORKA
Want to see ORKA full AI Analyst Report?
Top Page
Oruka Therapeutics
(NASDAQ:ORKA)
Select Model
Select Model
Rating:58Neutral
Price Target:
$66.00
▼(-4.24% Downside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by pre-revenue status with expanding losses and heavy cash burn, despite a strong, low-debt balance sheet. Technicals are moderately supportive but not strongly trending near-term, while valuation metrics are unfavorable due to negative earnings. A major offset is the positive Phase 2 clinical update, which improves the risk/reward outlook if subsequent trial data validates efficacy and durability.
Positive Factors
Low Leverage / Strong Balance Sheet
Extremely low leverage and a sizable equity base give Oruka durable financial flexibility, lowering refinancing and interest-rate risks. For a pre-revenue biotech, this reduces probability of forced asset sales or distressed financing and supports multi-year clinical programs.
Negative Factors
Pre-Revenue Status
Absence of product revenue means long-term value hinges entirely on trial outcomes and approvals. This structural dependence on successful clinical development elevates binary risk and leaves operating performance sensitive to trial timing, readouts, and regulatory milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Extremely low leverage and a sizable equity base give Oruka durable financial flexibility, lowering refinancing and interest-rate risks. For a pre-revenue biotech, this reduces probability of forced asset sales or distressed financing and supports multi-year clinical programs.
Read all positive factors
Oruka Therapeutics (ORKA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.66B
Dividend YieldN/A
Average Volume (3M)2.08M
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth54.61%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.39
Shares Outstanding60,312,100
10 Day Avg. Volume1,342,958
30 Day Avg. Volume2,083,098
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-15.64
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-31.30K
Enterprise Value/Ebitda-17.69
Forecast
1Y Price Target
$137.25Price Target Upside99.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.14
Revenue Forecast (FY)N/A
Oruka Therapeutics Business Overview & Revenue Model
Company Description
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA....
How the Company Makes Money
As a clinical-stage biotechnology company, Oruka Therapeutics does not have publicly available evidence of recurring product revenue from marketed therapies; as such, revenue from commercial drug sales is null. The company primarily funds operatio...
Oruka Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -71.00K | -83.00K | -27.00K | -114.00K | -91.00K | -93.00K |
| EBITDA | -125.61M | -121.97M | -82.23M | -9.81M | -19.23M | -9.64M |
| Net Income | -116.25M | -105.43M | -83.72M | -9.93M | -19.32M | -9.74M |
Balance Sheet | ||||||
| Total Assets | 504.48M | 488.62M | 396.02M | 43.09M | 54.92M | 50.43M |
| Cash, Cash Equivalents and Short-Term Investments | 388.83M | 337.04M | 375.65M | 42.45M | 53.36M | 49.07M |
| Total Debt | 1.81M | 1.93M | 968.00K | 383.00K | 483.00K | 450.00K |
| Total Liabilities | 17.76M | 16.69M | 13.80M | 1.41M | 3.88M | 3.91M |
| Stockholders Equity | 486.72M | 471.93M | 382.22M | 41.67M | 51.04M | 46.52M |
Cash Flow | ||||||
| Free Cash Flow | -91.19M | -88.42M | -58.03M | -10.91M | -18.80M | -7.74M |
| Operating Cash Flow | -90.92M | -88.21M | -57.84M | -10.91M | -18.76M | -7.72M |
| Investing Cash Flow | -154.05M | -96.75M | -330.13M | -2.00K | -43.00K | -19.00K |
| Financing Cash Flow | 210.91M | 170.31M | 449.54M | 0.00 | 23.09M | 48.45M |
Oruka Therapeutics Technical Analysis
Positive
68.92
Price Trends
58.60
Positive
45.58
Positive
34.33
Positive
Market Momentum
-0.34
Positive
47.51
Neutral
42.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Positive. The current price of 68.92 is above the 20-day moving average (MA) of 64.92, above the 50-day MA of 58.60, and above the 200-day MA of 34.33, indicating a neutral trend. The MACD of -0.34 indicates Positive momentum. The RSI at 47.51 is Neutral, neither overbought nor oversold. The STOCH value of 42.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORKA.
Oruka Therapeutics Risk Analysis
Oruka Therapeutics disclosed 1 risk factors in its most recent earnings report. Oruka Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oruka Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $1.74B | -5.01 | 442.91% | ― | 107.73% | 82.33% | |
60 Neutral | $1.42B | -5.37 | -35.89% | ― | ― | -63.41% | |
58 Neutral | $3.66B | -21.26 | -25.99% | ― | ― | 54.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.19B | -7.22 | -45.95% | ― | ― | -3.83% | |
45 Neutral | $372.58M | -3.56 | -486.41% | ― | 395.85% | 21.44% | |
42 Neutral | $372.78M | -13.46 | -39.75% | ― | -100.00% | -2.72% |
* Healthcare Sector Average
ORKA
Oruka Therapeutics
60.61
49.66
453.52%
VSTM
Verastem
4.24
-4.07
-48.98%
ANAB
AnaptysBio
59.71
46.09
338.27%
CMPX
Compass Therapeutics
2.07
-0.04
-1.90%
OLMA
Olema Pharmaceuticals
13.68
8.53
165.63%
BCAX
Bicara Therapeutics Inc.
21.68
11.70
117.23%
Oruka Therapeutics Corporate Events
Financial DisclosuresPrivate Placements and Financing
Oruka Therapeutics Completes Public Equity Offering Under Shelf
Neutral
Apr 30, 2026
On April 28, 2026, Oruka Therapeutics entered into an underwriting agreement with a syndicate of investment banks to offer 9,660,000 shares of common stock at $72.50 per share, including a 30‑day option for underwriters to buy up to 1,449,00...
Business Operations and StrategyProduct-Related Announcements
Oruka Therapeutics Reports Strong Phase 2 Psoriasis Results
Positive
Apr 27, 2026
On April 27, 2026, Oruka Therapeutics reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis, with 63.5% of treated patients achieving complete skin clearance (PASI 100 and identical...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.